SUPPLEMENT TO:
Safe and Appropriate Use of GLP-1 RAs in Treating Adult Patients With T2D and Macrovascular Disease
Over the past decade, the type 2 diabetes (T2D) treatment landscape has evolved, allowing for more therapeutic options and the opportunity to tailor treatments to achieve patient treatment goals. In this video roundtable series, James LaSalle, DO; Lucia M. Novak, CRNP; and Lawrence Blonde, MD, MACE, FACP, discuss the mechanisms of action and clinical trial data for use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the safe and effective primary care management of individuals with T2D and macrovascular disease.
Video 1: Introduction to GLP-1 RAs
The panelists begin this segment with a review of macrovascular complications in T2D and the latest antihyperglycemic therapies with macrovascular benefits. They discuss the mechanisms of action and the benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, and GLP-1 RAs.
Video 2: Cardiovascular outcome trials (CVOTs) of GLP-1 RAs
The panelists discuss the CVOTs of various GLP-1 RAs, including details on atherosclerotic cardiovascular disease, heart failure, and risk factor outcomes. They also discuss a few ongoing clinical trials for the use of GLP-1 RAs in patients with T2D and heart failure.
Video 3: Real-world studies of GLP-1 RAs
The panelists review real-world evidence for cardiovascular benefits of GLP-1 RAs. This section closes with a discussion of the benefits and risks of treatment with GLP-1 RAs.
Video 4: Expert recommendations for GLP-1 RA use
In the final segment, the panelists review recommendations for the use of GLP-1 RAs in combination with other treatments. They also share their insights on where the treatment of T2D is headed, including the increasing emphasis on the management of obesity.
Video 1: Introduction to GLP-1 RAs
The panelists begin this segment with a review of macrovascular complications in T2D and the latest antihyperglycemic therapies with macrovascular benefits. They discuss the mechanisms of action and the benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, and GLP-1 RAs.
Abstract
Read the summary of the roundtable videos.
These videos aim to review the mechanisms of action, clinical trial data, and real-world evidence for the use of GLP-1 RAs in the safe and effective care of individuals with T2D and macrovascular disease.
Download
About the Panel
Disclosures
James LaSalle, DO, has disclosed the following relevant financial relationships:
Consultant and member of the speakers bureau for Novo Nordisk Inc
Lucia M. Novak, CRNP, has disclosed the following relevant financial relationships:
Consultant, speaker, and/or advisor for Abbott Diabetes Care, Novo Nordisk, Provention Bio, Xeris
Lawrence Blonde, MD, MACE, FACP, has disclosed the following relevant financial relationships:
Consultant for Corcept Therapeutics, Gilead, Janssen Pharmaceuticals Inc, Lyndra Therapeutics, Merck, Novo Nordisk, Salix Pharmaceuticals, Sanofi, and member of the speakers bureau for Sanofi
Funding
This digital publication was funded by Novo Nordisk Inc., Plainsboro, NJ.
Authors received no remuneration for their development of this digital publication.
Acknowledgement
The authors acknowledge the professional medical writing support from Amy Ross, PhD, PRECISIONscientia, Yardley, PA, which was supported financially by Novo Nordisk Inc., Plainsboro, NJ.